Rational Design, Synthesis, and Biological Evaluation of New Substituted Dihydropyrimidinones as Antibacterial Agents and β‐Lactamase Inhibitors
Ahmed M. Soliman, Heba Abdelrasheed Allam, Walaa R. Mahmoud, Bassem H. Naguib · 2026
Read Rational Design, Synthesis, and Biological Evaluation of New Substituted Dihydropyrimidinones as Antibacterial Agents and β‐Lactamase Inhibitors by Ahmed M. Soliman, Heba Abdelrasheed Allam, Walaa R. Mahmoud, Bassem H. Naguib (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13438106.txt.
Description
Soliman and colleagues design a fresh family of compounds that both attack bacteria and shield antibiotics from bacterial defense enzymes. Beta lactamase enzymes break penicillin type drugs, a core driver of drug resistance. Their 2026 study builds a series of dihydropyrimidinones, ring shaped molecules. It tests them against two Gram positive and one Gram negative bacterial species, then against resistant strains and the purified defense enzyme.
Most compounds showed moderate bacteria killing next to the standard drug amoxicillin. Against resistant strains the compounds acted as boosters, restoring partner drug action by blocking the defense enzyme. Three leads, coded 3d, 3i, and 7b, blocked the purified enzyme at lower doses than clavulanic acid, the standard blocker used in clinics. The team names those three as hits worth refining into selective, stronger blockers for resistant infections.
Catalog record
| CREATOR | Ahmed M. Soliman, Heba Abdelrasheed Allam, Walaa R. Mahmoud, Bassem H. Naguib |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 59 KB |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |